• The Trauma Surgery of Emergency Center, Lanzhou University Second Hospital, Lanzhou 730030, Gansu Province, China;
LIPei-wu, Email: wuzi360@126.com
Export PDF Favorites Scan Get Citation

Objective To investigate the role of somatostatin in gastrointestinal function after operation for treatment of abdominal injury patients. Methods Sixty patients with abdominal trauma were divided into somatostatin in treatment group (n=30) and the conventional treatment control group (n=30). The amount of gastrointestinal decompression drainage, bowel sounds recovery time, exhaust time, defecation time, and the levels of serum C reactive protein, TNF-α, IL-6, and IL-8 after operation in two groups were observed. Results Somatostatin treatment group recovery time of bowel sounds, exhaust time, and defecation time were earlier than the control group, hospitalization time shortened, and the amount of gastrointestinal decompression drainage reduced (P < 0.05), The levels of serum C reactive protein, TNF-α, IL-6 and IL-8 of somatostatin treatment group were lower than those in control group (P < 0.05), and the magnitude of decline above index in the somatostatin treatment group were greater than that in the control group (P < 0.05). Conclusion Somatostatin can promote the recovery of gastrointestinal function in patients after operation in abdominal injury.

Citation: LIPei-wu, WANGXian-kun, FUXu, WANGBin-jun, YANBo, CUIHong-bing, BAITian-shuo. The Role of Somatostatin in Gastrointestinal Function after Operation for Treatment of Abdominal Injury. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(1): 56-59. doi: 10.7507/1007-9424.20160015 Copy

Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved

  • Previous Article

    Progress and Application of Medical Data Mining under the Background of Big Data
  • Next Article

    Effect on Liver Metastases of Intraoperative and Postoperative Portal Vein Chemotherapy and Combined with FOLFOX4 regimen chemotherapy for Patients with Obstrutive Colorectal Cancer